Leymus innovatus

MDxHealth Announces Completion of Share Consolidation, and Update of Outstanding Shares and Voting Rights

Retrieved on:

Monday, November 13, 2023

Sale, Disclosure, Update, Exercise, ADS, EUR, American depositary receipt, Leymus innovatus, ISIN, Security (finance), Brussels Stock Exchange

MDxHealth Announces Completion of Share Consolidation, and Update of Outstanding Shares and Voting Rights

Key Points:

MDxHealth Announces Completion of Share Consolidation, and Update of Outstanding Shares and Voting Rights
IRVINE, CA, and HERSTAL, BELGIUM – November 13, 2023 – MDxHealth SA (NASDAQ/Euronext: MDXH) ("mdxhealth" or the "Company"), a commercial-stage precision diagnostics company, today announces that it completed the share consolidation with respect to all its outstanding shares by means of a 1-for-10 reverse stock split (the "Share Consolidation"), the details of which were announced by press release on November 6, 2023.
After close of trading on the regulated market Euronext Brussels, all 272,880,936 Company's shares (ISIN BE0003844611) were consolidated into a new and reduced number of 27,288,093 Company's shares (ISIN BE0974461940).
In consequence, today, November 13, 2023, was the last trading day of the old 272,880,936 Company's shares (ISIN BE0003844611) on the regulated market of Euronext Brussels.
As a result of the Share Consolidation, all Company's American Depositary Shares ("ADSs"), trading on Nasdaq, now represent one (1) new share (instead of ten (10) old share previously), and each holder of subscription rights issued by the Company now have to exercise subscription rights with respect to at least 10 Company's shares prior the Share Consolidation in order to subscribe for one Company's share after the Share Consolidation.

Mdxhealth's New Share Capital Amount and New Number of Shares

Retrieved on:

Friday, October 20, 2023

Leymus innovatus, Genomics, Disclosure, Acquisition, Genomic Health, American depositary receipt, Oncotype (Denmark), ADS, EUR, USD, Article, Security (finance)

IRVINE, CA, and HERSTAL, BELGIUM – October 20, 2023 – MDxHealth SA (NASDAQ/Euronext: MDXH) ("mdxhealth" or the "Company"), a commercial-stage precision diagnostics company, today a announces, in accordance with Article 15 of the Belgian Act of May 2, 2007 on the disclosure of major participations in issuers of which shares are admitted to trading on a regulated market and regarding miscellaneous provisions, that in the context of a capital increase completed on October 20, 2023, the Company's share capital has increased from EUR 163,471,629.58 to EUR 164,302,752.89 and the number of issued and outstanding shares has increased from 270,380,936 to 272,880,936 ordinary shares, through the issuance of a total of 2,500,000 new shares.

Key Points:

IRVINE, CA, and HERSTAL, BELGIUM – October 20, 2023 – MDxHealth SA (NASDAQ/Euronext: MDXH) ("mdxhealth" or the "Company"), a commercial-stage precision diagnostics company, today a announces, in accordance with Article 15 of the Belgian Act of May 2, 2007 on the disclosure of major participations in issuers of which shares are admitted to trading on a regulated market and regarding miscellaneous provisions, that in the context of a capital increase completed on October 20, 2023, the Company's share capital has increased from EUR 163,471,629.58 to EUR 164,302,752.89 and the number of issued and outstanding shares has increased from 270,380,936 to 272,880,936 ordinary shares, through the issuance of a total of 2,500,000 new shares.
The new shares were issued pursuant to the amendment, announced on August 23, 2023, to the asset purchase agreement for the acquisition by the Company of the Oncotype DX® GPS (Genomic Prostate Score®) test from Genomic Health, Inc. (a subsidiary of Exact Sciences Corporation).
In addition to the outstanding shares of the Company:
a total of 18,560,124 subscription rights of the Company are outstanding, which entitles their holders (assuming all subscription rights are granted and exercised) to subscribe to a total of 18,560,124 new shares with voting rights; and
under the loan and security agreement entered into by the Company and Innovatus Capital Partners in August 2022, Innovatus has the right to convert, prior to August 2, 2025, up to 15% of the outstanding principal amount of the loans (by means of a contribution in kind of the relevant payables due by the Company under the loans) into American Depositary Shares ("ADSs") of the Company (each representing 10 ordinary shares of the Company) at a conversion price per ADS equal to USD 11.21 (i.e., USD 1.121 per share on the basis of the ratio of 1 ADS per 10 shares).

MDxHealth Announces Update of Outstanding Shares and Voting Rights

Retrieved on:

Wednesday, March 8, 2023

EUR, American depositary receipt, ADS, Leymus innovatus, Article, Disclosure, Security (finance)

IRVINE, CA, and HERSTAL, BELGIUM – March 8, 2023 – MDxHealth SA (NASDAQ/Euronext: MDXH) (“mdxhealth” or the “Company“), a commercial-stage precision diagnostics company, today announced, in accordance with Article 15 of the Belgian Act of May 2, 2007 on the disclosure of major participations in issuers of which shares are admitted to trading on a regulated market and regarding miscellaneous provisions, that in the context of the capital increase that was announced on March 6, 2023 and completed on March 8, 2023, its share capital has increased from EUR 160,658,690.06 to EUR 163,471,629.58, and the number of issued and outstanding shares has increased from 262,880,936 to 270,380,936 ordinary shares, through the issuance of a total of 7,500,000 new shares.

Key Points:

IRVINE, CA, and HERSTAL, BELGIUM – March 8, 2023 – MDxHealth SA (NASDAQ/Euronext: MDXH) (“mdxhealth” or the “Company“), a commercial-stage precision diagnostics company, today announced, in accordance with Article 15 of the Belgian Act of May 2, 2007 on the disclosure of major participations in issuers of which shares are admitted to trading on a regulated market and regarding miscellaneous provisions, that in the context of the capital increase that was announced on March 6, 2023 and completed on March 8, 2023, its share capital has increased from EUR 160,658,690.06 to EUR 163,471,629.58, and the number of issued and outstanding shares has increased from 262,880,936 to 270,380,936 ordinary shares, through the issuance of a total of 7,500,000 new shares.
In addition to the outstanding shares of the Company:
a total of 13,895,280 subscription rights of the Company is outstanding, which entitles their holders (assuming all subscription rights are granted and exercised) to subscribe to a total of 13,895,280 new shares with voting rights;
under the loan agreement entered into by the Company and Kreos Capital in July 2021, a drawdown fee equal to 7% of the amounts drawn down under the loan agreement (being EUR 630,000 in aggregate) remains outstanding as a payable due by the Company (without accruing interest), and is convertible into ordinary shares with voting rights by means of a contribution in kind of the payable by Kreos Capital to the share capital of the Company at a price of EUR 0.85 per share; and
under the loan and security agreement entered into by the Company and Innovatus Capital Partners in August 2022, Innovatus has the right to convert, prior to August 2, 2025, up to 15% of the outstanding principal amount of the loans (by means of a contribution in kind of the relevant payables due by the Company under the loans) into American Depositary Shares ("ADSs") of the Company (each representing 10 ordinary shares of the Company) at a conversion price per ADS equal to USD 11.21 (i.e., USD 1.121 per share on the basis of the ratio of 1 ADS per 10 shares).

MDxHealth Announces Update of Outstanding Shares and Voting Rights and Update of Financial Calendar

Retrieved on:

Wednesday, February 15, 2023

Leymus innovatus, Article, American depositary receipt, Disclosure, ADS, EUR, Security (finance)

IRVINE, CA, and HERSTAL, BELGIUM – February 15, 2023 – MDxHealth SA (NASDAQ/Euronext: MDXH) (“mdxhealth” or the “Company“), a commercial-stage precision diagnostics company, today announced, in accordance with Article 15 of the Belgian Act of May 2, 2007 on the disclosure of major participations in issuers of which shares are admitted to trading on a regulated market and regarding miscellaneous provisions, that in the context of the capital increase that was announced on February 1, 2023 and completed on February 7, 2023, its share capital has increased from EUR 123,539,165.19 to EUR 160,658,690.06, and the number of issued and outstanding shares has increased from 162,880,936 to 262,880,936 ordinary shares, through the issuance of a total of 100,000,000 new shares.

Key Points:

IRVINE, CA, and HERSTAL, BELGIUM – February 15, 2023 – MDxHealth SA (NASDAQ/Euronext: MDXH) (“mdxhealth” or the “Company“), a commercial-stage precision diagnostics company, today announced, in accordance with Article 15 of the Belgian Act of May 2, 2007 on the disclosure of major participations in issuers of which shares are admitted to trading on a regulated market and regarding miscellaneous provisions, that in the context of the capital increase that was announced on February 1, 2023 and completed on February 7, 2023, its share capital has increased from EUR 123,539,165.19 to EUR 160,658,690.06, and the number of issued and outstanding shares has increased from 162,880,936 to 262,880,936 ordinary shares, through the issuance of a total of 100,000,000 new shares.
In addition to the outstanding shares of the Company:
a total of 13,895,280 subscription rights of the Company is outstanding, which entitles their holders (assuming all subscription rights are granted and exercised) to subscribe to a total of 13,895,280 new shares with voting rights;
under the loan agreement entered into by the Company and Kreos Capital in July 2021, a drawdown fee equal to 7% of the amounts drawn down under the loan agreement (being EUR 630,000 in aggregate) remains outstanding as a payable due by the Company (without accruing interest), and is convertible into ordinary shares with voting rights by means of a contribution in kind of the payable by Kreos Capital to the share capital of the Company at a price of EUR 0.85 per share; and
under the loan and security agreement entered into by the Company and Innovatus Capital Partners in August 2022, Innovatus has the right to convert, prior to August 2, 2025, up to 15% of the outstanding principal amount of the loans (by means of a contribution in kind of the relevant payables due by the Company under the loans) into American Depositary Shares ("ADSs") of the Company (each representing 10 ordinary shares of the Company) at a conversion price per ADS equal to USD 11.21 (i.e., USD 1.121 per share on the basis of the ratio of 1 ADS per 10 shares).
In addition, the Company announces that its financial calendar for 2023 shall be as follows:

MDxHealth Provides Updated and Supplemental Financial Information Related to Acquisition of GPS Test

Retrieved on:

Friday, January 20, 2023

Financial statement, Exact sciences, Security (finance), Genomic Health, Urology, Form 6-K, Oncotype (Denmark), Exhibit, Acquisition, Genomics, GPS, Bank, Leymus innovatus

IRVINE, CA, and HERSTAL, BELGIUM – January 20, 2023 – MDxHealth SA (NASDAQ/Euronext: MDXH), a commercial-stage precision diagnostics company, today provided supplemental information related to its acquisition of the Oncotype DX® GPS (Genomic Prostate Score®) test on August 2, 2022 (the “GPS Test Acquisition”), from Genomic Health, Inc., a subsidiary of Exact Sciences Corporation (“Exact Sciences”).

Key Points:

IRVINE, CA, and HERSTAL, BELGIUM – January 20, 2023 – MDxHealth SA (NASDAQ/Euronext: MDXH), a commercial-stage precision diagnostics company, today provided supplemental information related to its acquisition of the Oncotype DX® GPS (Genomic Prostate Score®) test on August 2, 2022 (the “GPS Test Acquisition”), from Genomic Health, Inc., a subsidiary of Exact Sciences Corporation (“Exact Sciences”).
In addition, mdxhealth completed its integration and restructuring of the urology focused sales and customer success teams.
In addition, one-time additional financial expense of approximately $1.2 million related to replacing the Company’s debt facility was recorded.
These financial statements provide detailed disclosures, among other things, on the GPS Test Acquisition as well as the new debt facility with Innovatus which replaced the Kreos debt facility.

MDxHealth Reports Half Year 2022 Results

Retrieved on:

Thursday, August 25, 2022

Total revenue for the first half of 2022 was $13.0 million compared to total revenue of $10.7 million for the first half of 2021, an increase of 21%.

Key Points:

Total revenue for the first half of 2022 was $13.0 million compared to total revenue of $10.7 million for the first half of 2021, an increase of 21%.
Gross profit on products and services for the first half of 2022 was $5.8 million as compared to $5.2 million for the first half of 2021.
Gross margins on products and services declined to 44.4% for the first half of 2022 as compared to 48.6% for the same period in 2021, primarily due to timing of cash receipts for our UTI test, which is expected to reverse in the second half of 2022.
For more information, visit mdxhealth .com and follow us on social media at: twitter.com/ mdxhealth , facebook.com/ mdxhealth and linkedin.com/company/ mdxhealth .

Mdxhealth Acquires Oncotype DX® GPS Prostate Cancer Business from Exact Sciences and Reports Preliminary Half Year 2022 Results

Retrieved on:

Tuesday, August 2, 2022

---Conference Call and Webcast Today at 4:30PM ET/ 10:30PM CET

Key Points:

Additionally, the Company reported strong preliminary financial results for the half year ended June 30, 2022 and raised its current full year 2022 revenue guidance.
We also believe this acquisition positions mdxhealth as one of the leaders in the urology and prostate cancer space with one of the most comprehensive menus of precision diagnostics.
Our expanded menu provides clear and clinically actionably results to guide both patients and clinicians through the complex and often confounding prostate cancer diagnostic pathway.
Kevin Conroy, Chairman and CEO of Exact Sciences commented: We believe the mdxhealth team is well positioned to serve patients and customers in the urology space.

Blinker Secures Capital Raise and Licensing Agreement from Flagship Credit Acceptance

Retrieved on:

Tuesday, August 2, 2022

Today, Blinker, an automotive e-commerce technology and services company, and Flagship Credit Acceptance, a leading auto-finance provider managed by funds controlled by Perella Weinberg Partners Capital Management LP (PWPCM) and sub-advised by an affiliate of Innovatus Capital Partners, LLC (ICP), are pleased to announce they have completed a Series C capital raise with Flagship as the sole investor.

Key Points:

Today, Blinker, an automotive e-commerce technology and services company, and Flagship Credit Acceptance, a leading auto-finance provider managed by funds controlled by Perella Weinberg Partners Capital Management LP (PWPCM) and sub-advised by an affiliate of Innovatus Capital Partners, LLC (ICP), are pleased to announce they have completed a Series C capital raise with Flagship as the sole investor.
We are excited for Flagship Credit Acceptance to launch a direct-to-consumer experience that leverages machine learning, vision technology and self-service loan origination powered by Blinkers technology, said Rod Buscher, Founder and CEO of Blinker.
The investment in Blinker will allow Flagship to provide accessible lending across our expanding product set while adding significant operational efficiencies, stated Bob Hurzeler, Chief Executive Officer of Flagship Credit Acceptance.
Flagship Credit Acceptance LLC ( http://www.flagshipcredit.com ), headquartered in Chadds Ford, Pennsylvania, with offices in Coppell, Texas, and Tempe, Arizona, helps auto shoppers obtain financing.

Syapse Announces $35 Million Growth Investment with Innovatus Capital Partners to Expand Delivery of Real-World Evidence Through Syapse’s Learning Health Network

Retrieved on:

Wednesday, July 27, 2022

The investment is led by an affiliate of Innovatus Capital Partners, LLC (Innovatus) , with participation from existing investors including Ally Bridge Group, Merck Global Health Innovation Fund, Northpond Ventures, Revelation Alpine LLC, Safeguard Scientifics, and Social Capital.

Key Points:

The investment is led by an affiliate of Innovatus Capital Partners, LLC (Innovatus) , with participation from existing investors including Ally Bridge Group, Merck Global Health Innovation Fund, Northpond Ventures, Revelation Alpine LLC, Safeguard Scientifics, and Social Capital.
Innovatus Capital Partners, LLC, is an independent adviser and asset management firm with approximately $1.7B in assets under management.
The firm has a dedicated team of life sciences investment professionals with deep experience in healthcare, including life sciences.
To date the Innovatus Life Sciences Strategy has made over $1.1B in capital commitments for debt and equity support.

Innovatus Capital Partners Acquires Three State-of-the-Art Office Towers in High-Growth Area Near Seattle; LPC West to Provide Property Management Services

Retrieved on:

Tuesday, April 19, 2022

LPC West, the West Coast arm of national real estate firm Lincoln Property Company, has been retained to provide property management services.

Key Points:

LPC West, the West Coast arm of national real estate firm Lincoln Property Company, has been retained to provide property management services.
Innovatus is proud to add Triton Towers to our portfolio as it embodies another durable asset with optionality through a mixed-use density plan.
In December 2021, Innovatus acquired The Pinnacle, a five-story office building in the heart of Rancho Bernardo, with LPC West onboard to provide property management services.
Innovatus Capital Partners, LLC, is an independent adviser and portfolio management firm with approximately $1.7B in assets under management.